California Public Employees Retirement System increased its holdings in shares of QuidelOrtho Co. (NASDAQ:QDEL – Get Rating) by 5.9% in the second quarter, Holdings Channel.com reports. The fund owned 78,302 shares of the company’s stock after buying an additional 4,382 shares during the quarter. California Public Employees Retirement System’s holdings in QuidelOrtho were worth $7,609,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also bought and sold shares of the company. State Street Corp raised its position in QuidelOrtho by 7.0% during the 1st quarter. State Street Corp now owns 1,106,702 shares of the company’s stock valued at $124,460,000 after purchasing an additional 72,308 shares in the last quarter. Dimensional Fund Advisors LP raised its position in QuidelOrtho by 19.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 610,752 shares of the company’s stock valued at $68,686,000 after purchasing an additional 100,810 shares in the last quarter. Lazard Asset Management LLC raised its position in QuidelOrtho by 934.5% during the 2nd quarter. Lazard Asset Management LLC now owns 514,322 shares of the company’s stock valued at $49,981,000 after purchasing an additional 464,604 shares in the last quarter. TD Asset Management Inc. raised its position in shares of QuidelOrtho by 31.2% in the 2nd quarter. TD Asset Management Inc. now owns 458,302 shares of the company’s stock worth $44,538,000 after acquiring an additional 108,901 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of QuidelOrtho by 6.7% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 317,543 shares of the company’s stock worth $35,711,000 after acquiring an additional 20,034 shares in the last quarter. 87.20% of the stock is owned by institutional investors.
QuidelOrtho Stock Down 0.5 %
Shares of QDEL stock opened at $88.15 on Thursday. QuidelOrtho Co. has a 1-year low of $66.88 and a 1-year high of $180.06. The stock’s fifty day moving average price is $81.03 and its 200 day moving average price is $89.95. The company has a debt-to-equity ratio of 0.52, a current ratio of 1.66 and a quick ratio of 1.04. The company has a market cap of $5.82 billion, a price-to-earnings ratio of 4.69 and a beta of 0.28.
Wall Street Analysts Forecast Growth
QuidelOrtho Corporation focuses on the development and manufacture of diagnostic testing technologies across the continuum of healthcare testing needs. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.
- Get a free copy of the StockNews.com research report on QuidelOrtho (QDEL)
- Three CBD Stocks to Dominate a Budding Industry
- Microsoft Shares: Is it Time to Back Up the Truck?
- Salesforce Cuts Labor, Shows Strong Earnings Despite Challenges
- Is the 60/40 Portfolio Mix Still in Vogue?
- Institutional Support for Analog Devices Remains High
Receive News & Ratings for QuidelOrtho Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QuidelOrtho and related companies with MarketBeat.com's FREE daily email newsletter.